tiprankstipranks
Advertisement
Advertisement

KALV Stock Latest News

KalVista downgraded to Neutral from Buy at H.C. Wainwright
The FlyKalVista downgraded to Neutral from Buy at H.C. Wainwright
4d ago
KALV
KalVista downgraded to Hold from Buy at Needham
PremiumThe Fly
KalVista downgraded to Hold from Buy at Needham
4d ago
KALV
KalVista downgraded to Hold from Buy at JonesResearch
PremiumThe Fly
KalVista downgraded to Hold from Buy at JonesResearch
5d ago
KALV
KalVista Downgraded to $27 Target as Chiesi’s All-Cash Takeout Caps Near-Term Upside, Supporting Hold Rating
PremiumRatings
KalVista Downgraded to $27 Target as Chiesi’s All-Cash Takeout Caps Near-Term Upside, Supporting Hold Rating
5d ago
KALV
KalVista downgraded to Market Perform from Outperform at Leerink
PremiumThe Fly
KalVista downgraded to Market Perform from Outperform at Leerink
5d ago
KALV
KalVista downgraded to Market Perform from Outperform at Citizens
PremiumThe FlyKalVista downgraded to Market Perform from Outperform at Citizens
5d ago
KALV
KalVista moved to No Rating at BofA
Premium
The Fly
KalVista moved to No Rating at BofA
5d ago
KALV
Midday Fly By: Seagate reports Q3 beat, Visa reports mixed Q2
Premium
The Fly
Midday Fly By: Seagate reports Q3 beat, Visa reports mixed Q2
5d ago
V
BE
Chiesi to Acquire KalVista Pharmaceuticals in Cash Merger
PremiumCompany Announcements
Chiesi to Acquire KalVista Pharmaceuticals in Cash Merger
6d ago
8K
KALV
Chiesi Group to acquire KalVista for $27.00 per share in cash
PremiumThe Fly
Chiesi Group to acquire KalVista for $27.00 per share in cash
6d ago
KALV
3 ‘Strong Buy’ Stocks With Up to 180% Upside to Buy Now, According to Top Analysts, 4/16/2026
PremiumMarket News
3 ‘Strong Buy’ Stocks With Up to 180% Upside to Buy Now, According to Top Analysts, 4/16/2026
19d ago
ACRS
KALV
Ekterly: Strong Global Launch Momentum and Pediatric Upside Support Multi‑Year Growth and $39 Price Target
PremiumRatings
Ekterly: Strong Global Launch Momentum and Pediatric Upside Support Multi‑Year Growth and $39 Price Target
28d ago
KALV
KalVista announces interim Phase 3 data from KONFIDENT-KID trial of EKTERLY
PremiumThe FlyKalVista announces interim Phase 3 data from KONFIDENT-KID trial of EKTERLY
1M ago
KALV
Sustained EKTERLY Uptake and Shift Toward Oral HAE Therapy Underpin Buy Rating on KalVista
Premium
Ratings
Sustained EKTERLY Uptake and Shift Toward Oral HAE Therapy Underpin Buy Rating on KalVista
1M ago
KALV
KalVista price target lowered to $28 from $29 at Citizens
Premium
The Fly
KalVista price target lowered to $28 from $29 at Citizens
1M ago
KALV
KalVista price target raised to $42 from $39 at Stifel
PremiumThe Fly
KalVista price target raised to $42 from $39 at Stifel
1M ago
KALV
KalVista reports 8M EPS ($2.03) vs. ($2.30) last year
PremiumThe Fly
KalVista reports 8M EPS ($2.03) vs. ($2.30) last year
1M ago
KALV
KalVista sees cash runway through profitability
PremiumThe Fly
KalVista sees cash runway through profitability
1M ago
KALV
Early Outperformance and Expanding On‑Demand HAE Opportunity Justify Buy Rating on KalVista
PremiumRatings
Early Outperformance and Expanding On‑Demand HAE Opportunity Justify Buy Rating on KalVista
2M ago
KALV
KalVista announces new data from sebetralstat clinical trial program
PremiumThe FlyKalVista announces new data from sebetralstat clinical trial program
2M ago
KALV
KalVista announces inclusion of Ekterly on Hereditary Angioedema guideline
Premium
The Fly
KalVista announces inclusion of Ekterly on Hereditary Angioedema guideline
3M ago
KALV
KalVista price target raised to $35 from $30 at TD Cowen
Premium
The Fly
KalVista price target raised to $35 from $30 at TD Cowen
3M ago
KALV

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >